GD2抗体达妥昔单抗β治疗神经母细胞瘤护理专家共识  

Expert consensus on GD2 antibody dinutuximab beta for neuroblastoma care

作　　者：王春立[1] 武莹[1] 何梦雪[2] 苏玲 张洪燕[4] 郭欣[1] 程方方 李丹 孙丹[6] 王翠[7] WANG Chunli;WU Ying;HE Mengxue;SU Ling;ZHANG Hongyan;GUO Xin;CHENG Fangfang;LI Dan;SUN Dan;WANG Cui(Beijing Children′s Hospital,Capital Medical University/National Center for Children′s Health,Beijing 100045 China)

机构地区：[1]国家儿童医学中心,首都医科大学附属北京儿童医院,北京100045 [2]国家儿童医学中心,上海交通大学医学院附属上海儿童医学中心 [3]天津医科大学肿瘤医院 [4]上海交通大学医学院附属新华医院 [5]山东第一医科大学附属肿瘤医院 [6]武汉儿童医院 [7]首都儿科研究所附属儿童医院

出　　处：《护理研究》2024年第6期941-947,共7页Chinese Nursing Research

基　　金：中华护理学会护理专项项目,编号:ZHKY202202。

摘　　要：基于国内外临床研究报告以及本研究参与人员临床实践经验,通过文献分析、专家函询及专家研讨对神经节苷脂-2(GD2)抗体达妥昔单抗β治疗神经母细胞瘤的相关内容进行深入研究,最终形成包括准备以及要求、药品配制、药品输注、输注期间护理以及不良反应观察与护理等内容的GD2抗体达妥昔单抗β治疗神经母细胞瘤护理专家共识。Based on clinical research reports in China and abroad,as well as clinical practice experience of the participants in this study,relevant content on ganglioside‐2(GD2)antibody dinutuximab beta for neuroblastoma care was thoroughly investigated through literature analysis,expert inquiries,and expert discussions.The final expert consensus on the use of GD2 antibody dinutuximab beta for neuroblastoma care was formed,which included preparation and requirements,drug configuration,drug infusion,care during infusion,and observation and care of adverse reactions.

关 键 词：神经母细胞瘤(NB) 神经节苷脂-2(GD2) 达妥昔单抗β 护理 专家共识 

分 类 号：R473.73[医药卫生—护理学]